v3.26.1
BUSINESS SEGMENT INFORMATION (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Revenues $ 3,731.1 $ 3,527.3 $ 7,268.7 $ 6,872.4
Operating income 451.6 394.5 832.4 720.5
Intangible Asset, Finite-Lived, Amortization Expense (78.1) (68.3) (153.7) (137.9)
Net Restructuring Charges (5.1) (4.1) (11.5) (10.5)
Intangible Asset, Including Goodwill, Impairment Loss 0.0 0.0 0.0 0.0
Interest expense (61.1) (57.1) (116.2) (113.1)
Investment income 5.6 1.7 17.8 8.2
Equity method loss, net (6.2) (1.7) (11.3) (2.0)
Other, net (3.5) (32.7) (16.6) (33.7)
Earnings before income taxes 386.4 304.7 706.1 579.9
Operating Segments        
Segment Reporting [Line Items]        
Operating income 664.8 606.1 1,244.2 1,140.5
Intersegment Eliminations        
Segment Reporting [Line Items]        
Revenues 5.8 6.3 10.9 12.1
Diagnostics        
Segment Reporting [Line Items]        
Labor and Related Expense 1,223.4 1,155.1 2,411.5 2,278.7
Supplies Expense 625.1 591.3 1,238.6 1,177.9
Other Cost and Expense, Operating 461.5 454.2 899.5 884.4
Diagnostics | Operating Segments        
Segment Reporting [Line Items]        
Revenues 2,900.7 2,748.8 5,662.8 5,378.4
Depreciation 68.1 65.4 131.9 127.1
Operating income 522.6 482.8 981.3 910.3
Biopharma Laboratory Services        
Segment Reporting [Line Items]        
Labor and Related Expense 313.2 302.3 622.5 592.0
Supplies Expense 130.8 130.8 252.3 241.9
Freight 121.8 98.2 232.6 193.2
Other Cost and Expense, Operating 100.5 101.2 190.2 191.2
Biopharma Laboratory Services | Operating Segments        
Segment Reporting [Line Items]        
Revenues 836.2 784.8 1,616.8 1,506.1
Depreciation 27.7 29.0 56.3 57.6
Operating income 142.2 123.3 262.9 230.2
Corporate Segment [Member]        
Segment Reporting [Line Items]        
Operating income $ (130.0) $ (139.2) $ (246.6) $ (271.6)